Opinion

Video

Oral vs. IV HMAs: Considerations and Patient Guidance

Medical experts discuss considerations and patient guidance for oral and IV HMAs.

Video content above is prompted by the following:

  • What considerations can you share regarding switching patients from intravenous to oral therapies during myelodysplastic syndrome treatment, including factors such as efficacy, safety, and patient preferences?
  • What are the key differences between oral azacitidine and oral decitabine-cedazuridine in terms of interchangeability and patient management, and how do you navigate these discussions with your patients, particularly if they were receiving intravenous azacitidine initially?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo